Skip to main content
. 2015 Jan 15;5(2):674–688.

Table 3.

Univariate and multivariate analyses of clinicopathological factors and gene mutations in distant metastases

Metastases status No vs. Synchronous No vs. Metachronous Synchronous vs. Metachronous
No Syn. Meta. Univariate Multivariate Univariate Multivariate Univariate Multivariate
OR P value OR P value OR P value OR P value OR P value OR P value
Total patients (n) 96 92 93
Sex
    Male 51 63 60 1.917 0.032 2.457 0.038 1.604 0.113 2.233 0.024 0.837 0.568 0.757 0.512
    Female 45 29 33 1 - 1 - 1 - 1 - 1 - 1 -
Age
    < 55 31 37 30 1 - 1 - 1 - 1 - 1 - 1 -
    55-69 34 40 39 0.986 0.966 1.030 0.951 1.185 0.625 1.151 0.735 1.203 0.580 1.534 0.351
    > 69 31 15 24 0.405 0.023 0.187 0.003 0.800 0.550 0.627 0.340 1.973 0.098 3.585 0.032
Primary tumor location
    Right-sided 24 34 31 1 - 1 - 1 - 1 - 1 - 1 -
    Left-sided 26 27 24 0.733 0.417 0.671 0.446 0.715 0.392 0.556 0.202 0.975 0.946 0.922 0.879
    Rectum 46 31 38 0.476 0.036 0.400 0.070 0.640 0.201 0.404 0.041 1.344 0.393 1.467 0.430
Primary pT Stage
    1/2 16 11 9 1 - 1 - 1 - 1 - 1 - 1 -
    3 31 18 35 0.845 0.731 0.673 0.561 2.007 0.150 1.402 0.562 2.377 0.106 4.478 0.046
    4 49 63 49 1.870 0.151 1.161 0.811 1.778 0.214 1.243 0.692 0.951 0.917 1.240 0.751
Primary pN Stage
    0 45 30 34 1 - 1 - 1 - 1 - 1 - 1 -
    1 35 26 32 1.114 0.757 1.338 0.551 1.210 0.568 1.369 0.439 1.086 0.821 1.142 0.792
    2 16 36 27 3.375 0.001 4.579 0.006 2.233 0.039 3.361 0.010 0.662 0.248 0.863 0.773
Primary differentiation
    G1-G2 64 53 59 1 - 1 - 1 - 1 - 1 - 1 -
    G3-G4 32 39 34 1.472 0.201 1.336 0.335 1.153 0.642 1.042 0.912 0.783 0.417 0.967 0.934
Primary histological type
    Non-mucinous 76 74 80 1 - 1 - 1 - 1 - 1 - 1 -
    Mucinous 20 18 13 0.924 0.829 0.738 0.532 0.618 0.217 0.396 0.056 0.668 0.311 0.639 0.412
KRAS
    WT 68 49 49 1 - 1 - 1 - 1 - 1 - 1 -
    Codon 12 MT 24 36 23 2.082 0.023 2.271 0.086 1.330 0.411 2.278 0.054 0.639 0.181 0.709 0.472
    Codon 13 MT 4 7 21 2.429 0.175 2.085 0.407 7.286 0.001 11.857 < 0.001 3.000 0.022 3.764 0.049
BRAF
    WT 92 80 91 1 - 1 - 1 - 1 - 1 - 1 -
    MT 4 12 2 3.450 0.038 4.419 0.047 0.505 0.437 0.758 0.785 0.147 0.014 0.099 0.019
PIK3CA
    WT 83 72 78 1 - 1 - 1 - 1 - 1 - 1 -
    MT 13 20 15 1.774 0.143 1.977 0.204 1.228 0.617 1.195 0.720 0.692 0.331 0.458 0.133
PTEN
    WT 81 78 76 1 - 1 - 1 - 1 - 1 - 1 -
    MT 15 14 17 0.969 0.938 0.960 0.944 1.208 0.627 1.219 0.667 1.246 0.578 1.764 0.304
Pre-primary resection CEA
    < 5 ng/ml 51 18 50 1 - 1 - 1 - 1 - 1 - 1 -
    5-200 ng/ml 31 45 33 4.113 < 0.001 4.789 < 0.001 1.086 0.797 1.046 0.902 0.264 < 0.001 0.164 < 0.001
    > 200 ng/ml 1 25 1 70.833 < 0.001 80.799 < 0.001 1.020 0.989 0.756 0.862 0.140 < 0.001 0.005 < 0.001
    Unknow 13 4 9 0.872 0.829 0.772 0.735 0.706 0.466 0.834 0.749 0.810 0.750 0.619 0.547
Adjuvant CT
    Oral Fu 11 - 8 - - - - 1 - 1 - - - - -
    FOLFOX 72 - 71 - - - - 1.356 0.538 1.274 0.711 - - - -
    XELOX 7 - 11 - - - - 2.161 0.251 1.875 0.440 - - - -
    Unknow 6 - 3 - - - - 0.688 0.658 0.531 0.551 - - - -

Logistic regression model was used in the analyses. Syn.: synchronous; Meta.: metachronous; OR: odds ratio; WT: wild type; MT: mutant type; CEA: carcino-embryonic antigen; Adjuvant CT: adjuvant chemotherapy after primary tumor resection; Fu: fluorouracil; FOLFOX: fluorouracil, leucovorin, and oxaliplatin; XELOX: capecitabine and oxaliplatin.